A Randomized, Double Blind, Placebo Controlled Trial To Study Difference In Cognitive Learning Associated With Repeated Self-administration Of Remote Computer Tablet-based Application Assessing Dual-task Performance Based On Amyloid Status In Healthy Elderly Volunteers

Pfizer4 sites in 1 country97 target enrollmentSeptember 2014

ConditionsHealthy

InterventionsRitalin Placebo

DrugsRitalin Placebo

Overview

Phase: Not Applicable
Intervention: Ritalin
Conditions: Healthy
Sponsor: Pfizer
Enrollment: 97
Locations: 4
Primary Endpoint: divided attention performance
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to evaluate the difference in learning and performance measures associated with repeated use of an iPad video game (Akili Interactive's Project: EVO) in healthy elderly volunteers based on amyloid status.

Registry

clinicaltrials.gov

Start Date

September 2014

End Date

May 2016

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Pfizer

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy males and females between the ages of 70 and
•Subjects must have BMI of 17.5 to 32 kg/m2 and total body weight \> 110 pounds.
•Acceptable screening MRI and PET scans that pass quality control requirements.

Exclusion Criteria

•Co-morbid diagnosis of clinically documented Alzheimer's disease; - Significant cognitive impairment;
•MMSE (mini mental state examination) score \<26

Arms & Interventions

(Amyloid Negative)

Intervention: Ritalin

(Amyloid Negative)

Intervention: Placebo

Amyloid Positive

Intervention: Ritalin

Amyloid Positive

Intervention: Placebo

Outcomes

Primary Outcomes

divided attention performance

Time Frame: Day 0 - Day 28

The difference in effect of cognitive training on divided attention performance as measured by teh pre/post training change in interference cost on EVO dueal task assessment at Day 28.